Chronic Organ Transplant Rejection: Opportunities Await Improved Therapies

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Biology of Transplant Rejection
  • Immune Response in Tissue Rejection
    • T-Cell Activation
    • B-Cell Activation
    • Natural Killer Cell Response
  • Types of Rejection
  • Importance of HLA Matching in Preventing Organ Rejection
  • Post-Transplant Survival Rates
• Prevalence of Organ Transplantation
• Current Therapies
  • Treatment After Organ Transplantation
  • Overview of Commonly Used Agents for Maintenance Therapy
    • Azathioprine
    • Corticosteroids
    • Cyclosporine
    • Mycophenolate
    • Sirolimus
    • Tacrolimus
• 2007 Market for Anti-Rejection Therapies
• Emerging Therapies and Their Commercial Potential
  • Long-Acting Tacrolimus
  • CP-690550
  • Belatacept
• Outlook: Drivers, Constraints, and Development Strategies

Tables

• 1. Immune System Mediators and Their Functions
• 2. U.S. Sales of Leading Branded Agents (Organ Transplant Market Only) to Prevent Organ Rejection, 2007
• 3. Agents in U.S. Development for the Prevention of Chronic Rejection, 2007

Figures

• 1. Number of U.S. Organ Transplantations, 1988-2017
• 2. Number of U.S. Organ Transplants, by Organ, 2007
• 3. Mechanism of Action of Current Anti-Rejection Agents
• 4. U.S. Market Growth of Anti-Rejection Agents, 2000-2007
• 5. U.S. Market Share of Leading Anti-Rejection Agents, 2007
• 6. U.S. Prescribing Share of Leading Anti-Rejection Agents, 2007